Table 2 (A) Grade 3 or 4 adverse events suspected to be related to study drug; (B) adverse events suspected to be related to study drug (all grades, in ≥ 10% of patients).

	10 mg Reg 1	20 mgReg 1	40 mgReg 1	80 mgReg 1	150 mg Reg 1	300 mgReg 1	400 mgReg 1	300 mgReg 3	500 mgReg 3	700 mgReg 3	All patients
	N = 3	N = 4	N = 4	N = 4	N = 4	N = 7	N = 5	N = 8	N = 6	N = 6	N = 51
(A) Preferred term, n %
Thrombocytopenia	0	0	0	0	0	4 (57.1)	4 (80.0)	0	1 (16.7)	3 (50.0)	12 (23.5)
Lymphopenia	1 (33.3)	0	0	0	0	0	1 (20.0)	1 (12.5)	1 (16.7)	1 (16.7)	5 (9.8)
Neutropenia	0	0	0	0	0	1 (14.3)	1 (20.0)	0	1 (16.7)	3 (50.0)	6 (11.8)
Lipase increased	0	0	1 (25.0)	0	0	1 (14.3)	0	1 (12.5)	1 (16.7)	1 (16.7)	5 (9.8)
Leukopenia	0	0	0	0	0	1 (14.3)	2 (40.0)	0	0	1 (16.7)	4 (7.8)
Anaemia	0	0	0	0	0	2 (28.6)	0	0	0	2 (33.3)	4 (7.8)
White blood cell count decreased	0	0	0	0	0	3 (42.9)	1 (20.0)	0	0	0	4 (7.8)
Granulocytopenia	0	0	0	0	0	1 (14.3)	0	0	0	0	1 (2.0)
Nausea	0	0	0	0	0	0	0	1 (12.5)	1 (16.7)	0	2 (3.9)
Lymphocyte count decreased	0	0	0	0	0	1 (14.3)	0	0	0	0	1 (2.0)
Neutrophil count decreased	0	0	0	0	0	2 (28.6)	0	0	0	0	2 (3.9)
Hyperlipasaemia	0	0	0	0	0	0	0	0	0	1 (16.7)	1 (2.0)
Hyperlipidaemia	0	0	0	0	0	1 (14.3)	0	0	0	0	1 (2.0)
Proteinuria	0	0	0	0	0	0	1 (20.0)	0	0	0	1 (2.0)

ALT alanine aminotransferase, AST aspartate amino transferase, CPK creatine phosphokinase.
Adverse events suspected to be related to study drug (all grades, in ≥10% of patients.
Reg 1: 3qw dosing, 4-week treatment cycle, continuous; Reg 3: 3qw dosing, 3-week treatment cycle; 2 weeks on treatment and 1 week off treatment.

Search